Elicio Therapeutics, Inc. Payments of Merger Related Costs, Financing Activities
Elicio Therapeutics, Inc. (ELTX) reported Payments of Merger Related Costs, Financing Activities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities · last filed 2025-03-31
- Elicio Therapeutics, Inc. payments of merger related costs, financing activities for the quarter ending 2024-12-31 was $0.00.
- Elicio Therapeutics, Inc. payments of merger related costs, financing activities for the quarter ending 2024-09-30 was $0.00.
- Elicio Therapeutics, Inc. payments of merger related costs, financing activities for the quarter ending 2023-12-31 was -$2.00K.
- Elicio Therapeutics, Inc. payments of merger related costs, financing activities for the quarter ending 2023-09-30 was $0.00.
- Elicio Therapeutics, Inc. payments of merger related costs, financing activities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Elicio Therapeutics, Inc. payments of merger related costs, financing activities for fiscal 2023 was $2.36M.
- Elicio Therapeutics, Inc. payments of merger related costs, financing activities for fiscal 2022 was $0.00.
| Period end | Payments of Merger Related Costs, Financing Activities 3 month | Payments of Merger Related Costs, Financing Activities 6 month | Payments of Merger Related Costs, Financing Activities 9 month | Payments of Merger Related Costs, Financing Activities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$2.00K derived: sum of 2 quarters · filed 2025-03-31 | $2.36M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.37M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $2.37M 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |